The value behind a comprehensive assessment of the genomic alterations in a tumor has been consistently increasing with the availability of new therapeutic agents and better predictability of response. The regulatory and reimbursement for this type of assay evolved drastically over the last years. We will discuss how this change in environment provides strong value to adopt comprehensive genomic profiling in today's oncology care.